Summit Therapeutics (SMMT) Current Deferred Revenue (2018 - 2022)

Summit Therapeutics (SMMT) has reported Current Deferred Revenue for 5 consecutive years, with $3.2 million the latest figure, recorded in Q2 2022.

• Quarterly Current Deferred Revenue fell 56.95% year-over-year to $3.2 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $3.2 million (down 56.95% YoY) and the FY2021 annual result came in at $7.9 million, down 11.19% from the prior year.
• Current Deferred Revenue retreated to $3.2 million in Q2 2022 per SMMT's latest filing, from $5.1 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for SMMT reached as high as $18.6 million in Q1 2018 and fell as low as $464133.6 in Q4 2019.
• A 5-year average of $6.8 million and a median of $7.1 million in 2020 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2019 — Current Deferred Revenue slumped 94.21% — and 2020, when it jumped 512.02%.
• Year by year, Current Deferred Revenue stood at $8.0 million in 2018, then tumbled by 81.79% to $1.5 million in 2019, then soared by 512.02% to $8.9 million in 2020, then slipped by 11.19% to $7.9 million in 2021, then sank by 59.3% to $3.2 million in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $3.2 million, $5.1 million, and $7.9 million for Q2 2022, Q1 2022, and Q4 2021 respectively.